Correction of Brain Oligodendrocytes by AAVrh.10 Intracerebral Gene Therapy in Metachromatic Leukodystrophy Mice
Open accessAbstract
Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder characterized by accumulation of sulfatides in glial cells and neurons, the result of an inherited deficiency of arylsulfatase A (ARSA; EC 3.1.6.8) and myelin degeneration in the central and peripheral nervous systems. No effective treatment is currently available for the most frequent late infantile (LI) form of MLD, which results in rapid neurological degradation and early death after the onset of clinical manifestations. To potentially arrest or reverse disease progression, ARSA enzyme must be rapidly delivered to brain oligodendrocytes of patients with LI MLD. We previously showed that brain gene therapy with adeno-associated virus serotype 5 (AAV5) driving the expression of human ARSA cDNA under the control of the murine phosphoglycerate kinase (PGK) promoter alleviated most long-term disease manifestations in MLD mice. Herein, we evaluated the short-term effects of AAVrh.10 driving the expression of human ARSA cDNA under the control of the cytomegalovirus/β-actin hybrid (CAG/cu) promoter in 8-month-old MLD mice that already show marked sulfatide accumulation and brain pathology. Within 2 months, and in contrast to results with the AAV5-PGK-ARSA vector, a single intrastriatal injection of AAVrh.10cuARSA resulted in correction of brain sulfatide storage, accumulation of specific sulfatide species in oligodendrocytes, and associated brain pathology in the injected hemisphere. Better potency of the AAVrh.10cuARSA vector was mediated by higher neuronal and oligodendrocyte transduction, axonal transport of the AAVrh.10 vector and ARSA enzyme, as well as higher CAG/cu promoter driven expression of ARSA enzyme. These results strongly support the use of AAVrh.10cuARSA vector for intracerebral gene therapy in rapidly progressing early-onset forms of MLD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In prior studies, AAVrh.10 was found to be superior for widespread CNS expression compared with several serotypes, including AAV5.
“In prior studies, AAVrh.10 was found to be superior for widespread CNS expression than several serotypes, including AAV5.”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · see citing works
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872 · see citing works
Cearley, C. N., & Wolfe, J. H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.015 · Cited by 409 · see citing works
Peters, C., Steward, C. G., & on behalf of the NMDP, I. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703839 · Cited by 312 · see citing works
Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans, L., Wilson, J. M., Debyser, Z., & Baekelandt, V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.178 · Cited by 305 · see citing works
Biffi, A., Palma, M. D., Quattrini, A., Carro, U. D., Amadio, S., Visigalli, I., Sessa, M., Fasano, S., Brambilla, R., Marchesini, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419205 · Cited by 280 · see citing works
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
Parenti, G. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900036 · Cited by 274 · see citing works
Phenotype of arylsulfatase A-deficient mice: Relationship to human metachromatic leukodystrophy
Heß, B., Säftig, P., Hartmann, D., Coenen, R., Lüllmann‐Rauch, R., Goebel, H. H., Evers, M., FIGURA, K. V., D’Hooge, R., Nagels, G., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14821 · Cited by 263 · see citing works
Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice
Biffi, A., Capotondo, A., Fasano, S., Carro, U. D., Marchesini, S., Azuma, H., Malaguti, M. C., Amadio, S., Brambilla, R., Grompe, M., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28873 · Cited by 223 · see citing works
Fujita, N. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.6.711 · Cited by 222 · see citing works
Cearley, C. N., & Wolfe, J. H. N. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2185-07.2007 · Cited by 212 · see citing works
Klein, R. L., Dayton, R. D., Tatom, J. B., Henderson, K. M., & Henning, P. P. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300331 · Cited by 196 · see citing works
Expanded Repertoire of AAV Vector Serotypes Mediate Unique Patterns of Transduction in Mouse Brain
Cearley, C. N., Vandenberghe, L. H., Parente, M. K., Carnish, E. R., Wilson, J. M., & Wolfe, J. H. (2008) · Molecular Therapy · doi:10.1038/mt.2008.166 · Cited by 182 · see citing works
Sondhi, D., Hackett, N. R., Peterson, D. A., Stratton, J., Baad, M., Travis, K. M., Wilson, J. M., & Crystal, R. G. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300049 · Cited by 170 · see citing works
Self-citationLawlor, P. A., Bland, R. J., Mouravlev, A., Young, D., & During, M. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.170 · Cited by 161 · see citing works
Targeted Retrograde Gene Delivery for Neuronal Protection
Kaspar, B. K., Erickson, D. A., Schaffer, D. V., Hinh, L., Gage, F. H., & Peterson, D. A. (2002) · Molecular Therapy · doi:10.1006/mthe.2001.0520 · Cited by 147 · see citing works
Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain
Wang, C., Wang, C.-M., Clark, K. R., & Sferra, T. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302011 · Cited by 139 · see citing works
Efficient gene therapy-based method for the delivery of therapeutics to primate cortex
Kells, A. P., Hadaczek, P., Yin, D., Bringas, J., Varenika, V., Forsayeth, J., & Bankiewicz, K. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810682106 · Cited by 134 · see citing works
Passini, M. A., Lee, E. B., Heuer, G. G., & Wolfe, J. H. N. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06437.2002 · Cited by 130 · see citing works
Efficient Retrograde Neuronal Transduction Utilizing Self-complementary AAV1
Hollis, E. R., II, Kadoya, K., Hirsch, M. L., Samulski, R. J., & Tuszynski, M. H. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300367 · Cited by 124 · see citing works
Treating lysosomal storage disorders: Current practice and future prospects
Platt, F. M., & Lachmann, R. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.08.009 · Cited by 91 · see citing works
Hadaczek, P., Forsayeth, J., Mirek, H., Munson, K., Bringas, J., Pivirotto, P., L McBride, J., Davidson, B. L., & Bankiewicz, K. S. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.151 · Cited by 90 · see citing works
Sevin, C., Benraiss, A., Dam, D. V., Bonnin, D., Nagels, G., Vérot, L., Laurendeau, I., Vidaud, M., Gieselmann, V., Vanier, M., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi425 · Cited by 87 · see citing works
Self-citationDodiya, H. B., Bjorklund, T., Stansell III, J., Mandel, R. J., Kirik, D., & Kordower, J. H. (2010) · Molecular Therapy · doi:10.1038/mt.2009.216 · Cited by 86 · see citing works
Airavaara, M., Chiocco, M. J., Howard, D. B., Zuchowski, K. L., Peränen, J., Liu, C., Fang, S., Hoffer, B. J., Wang, Y., & Harvey, B. K. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.05.020 · Cited by 81 · see citing works
Hennig, A. K., Levy, B. K., Ogilvie, J. M., Vogler, C. A., Galvin, N. J., Bassnett, S., & Sands, M. S. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03302.2003 · Cited by 79 · see citing works
Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate
Colle, M.-A., Piguet, F., Bertrand, L., Raoul, S., Bièche, I., Dubreil, L., Sloothaak, D., Bouquet, C., Moullier, P., Aubourg, P. R., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp475 · Cited by 72 · see citing works
Self-citationChen, H., McCarty, D. M., Bruce, A. T., Suzuki, K., & Suzuki, K. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990215)55:4 · Cited by 71 · see citing works
Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis
Sondhi, D., Peterson, D. A., Edelstein, A., del Fierro, K., Hackett, N. R., & Crystal, R. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.04.022 · Cited by 68 · see citing works
Self-citationWittke, D., Hartmann, D., Gieselmann, V., & L�llmann-Rauch, R. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0883-6 · Cited by 67 · see citing works
Matzner, U., Lüllmann‐Rauch, R., Stroobants, S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.305 · Cited by 66 · see citing works
Matzner, U., HARZER, K., Learish, R., Barranger, J. A., & Gieselmann, V. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301232 · Cited by 66 · see citing works
A pedigree study of metachromatic leukodystrophy
Bass, N. H., Witmer, E. J., & Dreifuss, F. E. (1970) · Neurology · doi:10.1212/wnl.20.1.52 · Cited by 62 · see citing works
Sevin, C., Vérot, L., Benraiss, A., Dam, D. V., Bonnin, D., Nagels, G., Fouquet, F., Gieselmann, V., Vanier, M. T., Deyn, P. P. D., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302883 · Cited by 61 · see citing works
Self-citationSulfatide with short fatty acid dominates in astrocytes and neurons
Isaac, G., Pernber, Z., Gieselmann, V., Hansson, E. K., Bergquist, J., & Månsson, J. (2006) · FEBS Journal · doi:10.1111/j.1742-4658.2006.05195.x · Cited by 58 · see citing works
Axons mediate the distribution of arylsulfatase a within the mouse hippocampus upon gene delivery
Luca, T., Givogri, M. I., Perani, L., Galbiati, F., Follenzi, A., Naldini, L., & Bongarzone, E. R. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.438 · Cited by 54 · see citing works
Bredius, R. G. M., Laan, L. A. E. M., Lankester, A. C., Poorthuis, B. J. H. M., van Tol, M. J. D., Egeler, R. M., & Arts, W. F. M. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705581 · Cited by 45 · see citing works
Kurai, T., Hisayasu, S., Kitagawa, R., Migita, M., Suzuki, H., Hirai, Y., & Shimada, T. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300012 · Cited by 44 · see citing works
Foust, K. D., Flotte, T. R., Reier, P. J., & Mandel, R. J. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.104 · Cited by 37 · see citing works
Martino, S., Consiglio, A., Cavalieri, C., et al. (2005) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2005.01.018 · Cited by 27 · see citing works
Clinical, biochemical and molecular findings in a two‐generation Morquio A family
Tylki‐Szymańska, A., Czartoryska, B., Bunge, S., et al. (1998) · Clinical Genetics · doi:10.1111/j.1399-0004.1998.tb02747.x · Cited by 27 · see citing works
Transport of Arylsulfatase A across the Blood-Brain Barrier in Vitro
Matthes, F., Wölte, P., Böckenhoff, A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.189381 · Cited by 25 · see citing works
α-l-Iduronidase transport in neurites
Chen, F., Vitry, S., Hocquemiller, M., Desmaris, N., Ausseil, J., & Heard, J. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2005.11.017 · Cited by 22 · see citing works
Consiglio, A., Martino, S., Dolcetta, D., Angelis, M. G. C. D., Conese, M., Marchesini, S., Benaglia, G., Wrabetz, L. G., Orlacchio, A., Déglon, N., et al. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.010 · Cited by 21 · see citing works
Sangalli, A., Taveggia, C., Salviati, A., et al. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.14-2111 · Cited by 18 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Von Figura K. Gieselmann V. Jaeken J. Metachromatic leukodystrophy. In: Scriver C., editor; Beaudet A., editor; Sly W., editor; Valle D., editor. The Metabolic, Molecular Bases of Inherited Disease. 8th. McGraw-Hill; New York: 2001. pp. 3695–3724. [Google Scholar]
Cited by
Sorted by citations
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291 · see citing works
Self-citationAAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease
Rosenberg, J. B., Kaplitt, M. G., De, B. P., Chen, A., Flagiello, T., Salami, C., Pey, E., Zhao, L., Ricart Arbona, R. J., Monette, S., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.231 · Cited by 169 · see citing works
Self-citationAAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131 · see citing works
Glial promoter selectivity following AAV-delivery to the immature brain
von Jonquieres, G., Mersmann, N., Klugmann, C. B., Harasta, A. E., Lutz, B., Teahan, O., Housley, G. D., Fröhlich, D., Krämer-Albers, E.-M., & Klugmann, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065646 · Cited by 133 · see citing works
Gene therapy for metachromatic leukodystrophy
Rosenberg, J. B., Kaminsky, S. M., Aubourg, P., Crystal, R. G., & Sondhi, D. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23792 · Cited by 91 · see citing works
Self-citationThwaite, R., Pagès, G., Chillón, M., & Bosch, A. (2015) · Gene Therapy · doi:10.1038/gt.2014.103 · Cited by 76 · see citing works
Rosenberg, J. B., Sondhi, D., Rubin, D. G., Monette, S., Chen, A., Cram, S., De, B. P., Kaminsky, S. M., Sevin, C., Aubourg, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.239 · Cited by 58 · see citing works
Self-citationRosenberg, J. B., Chen, A., De, B. P., Dyke, J. P., Ballon, D. J., Monette, S., Ricart Arbona, R. J., Kaminsky, S. M., Crystal, R. G., & Sondhi, D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.269 · Cited by 41 · see citing works
Self-citationBucher, T., Dubreil, L., Colle, M.-A., Maquigneau, M., Deniaud, J., Ledevin, M., Moullier, P., & Joussemet, B. (2014) · Gene Therapy · doi:10.1038/gt.2014.16 · Cited by 40 · see citing works
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic, J., Li, Y., Gong, Y., & Eichler, F. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00443 · Cited by 16 · see citing works
- Authors
- Piguet, F., Sondhi, D., Piraud, M., Fouquet, F., Hackett, N. R., Ahouansou, O., Vanier, M.-T., Bieche, I., Aubourg, P., Crystal, R. G., Cartier, N., & Sevin, C.
- Affiliations
- Inserm (FR)
- Weill Cornell Medicine (US)
- Hospices Civils de Lyon (FR)
- University Paris-Descartes
- Corresponding author
- Sevin, Caroline
- ORCID
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2012-05-15
- Volume
- 23
- Issue
- 8
- Pages
- 903-914
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- PMC
- PMC3413898
- OpenAlex
- W2018332312
- Cited by
- 91
- References
- 45
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 6 · 2023: 10 · 2022: 1 · 2021: 13 · 2020: 7 · 2019: 4 · 2018: 7 · 2017: 2 · 2016: 5 · 2015: 9 · 2014: 11 · 2013: 5 · 2012: 2
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Human Gene Therapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission (241622)
- Institut National de la Santé et de la Recherche Médicale
- Association Européenne contre les Leucodystrophies
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (U01NS047458)
- Topics
- Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- metachromatic leukodystrophy, oligodendrocytes, sulfatide accumulation, late infantile MLD, axonal transport, myelin degeneration, lysosomal storage disease
- MeSH terms
- Dependovirus, Animals, Brain, Cerebroside-Sulfatase, Genetic Vectors, Humans, Leukodystrophy, Metachromatic, Neurons, Oligodendroglia, Phosphoglycerate Kinase, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
